LabCorp and Mount Sinai Health System Collaborate to Establish Digital and AI-Enabled Pathology Center of Excellence
Summary
BURLINGTON, N.C. & NEW YORK & AMSTERDAM--(BUSINESS WIRE)--LabCorp® (NYSE: LH) and the Mount Sinai Health System today announced another element in their shared goal of improving laboratory services and patient care. This, in addition to our new predictive AI-based tests, introduces the potential for optimization of treatment efficacy, and provides the opportunity for improved clinical outcomes,” said Carlos Cordon-Cardo, M.D., Ph.D., chairman of the Department of Pathology, Molecular and Cell-Based Medicine at Mount Sinai Health System and professor of Pathology, Genetics and Genomic Sciences, and Oncological Sciences at the Icahn School of Medicine at Mount Sinai. Don Scanlon, chief financial officer and chief of corporate services at Mount Sinai, added, “The Digital and AI-Enabled Pathology Center of Excellence stands to offer major operational efficiencies, extending our joint unique resources and intellectual assets more effectively to improve the lives of patients.” The Center of Excellence will include deployment of the Philips IntelliSite Pathology Solution at each of Mount Sinai’s eight hospitals and select ambulatory care locations. Implementation of the clinical Philips IntelliSite Pathology Solution is underway and Mount Sinai expects to begin its use in the next several months. Mount Sinais Kravis Childrens Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report.
